GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Keymed Biosciences Inc (HKSE:02162) » Definitions » LT-Debt-to-Total-Asset

Keymed Biosciences (HKSE:02162) LT-Debt-to-Total-Asset : 0.09 (As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is Keymed Biosciences LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Keymed Biosciences's long-term debt to total assests ratio for the quarter that ended in Dec. 2023 was 0.09.

Keymed Biosciences's long-term debt to total assets ratio increased from Dec. 2022 (0.01) to Dec. 2023 (0.09). It may suggest that Keymed Biosciences is progressively becoming more dependent on debt to grow their business.

Keymed Biosciences LT-Debt-to-Total-Asset Historical Data

The historical data trend for Keymed Biosciences's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Keymed Biosciences LT-Debt-to-Total-Asset Chart

Keymed Biosciences Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
LT-Debt-to-Total-Asset
0.04 0.04 0.01 0.01 0.09

Keymed Biosciences Semi-Annual Data
Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
LT-Debt-to-Total-Asset Get a 7-Day Free Trial Premium Member Only 0.01 0.01 0.01 0.07 0.09

Keymed Biosciences LT-Debt-to-Total-Asset Calculation

Keymed Biosciences's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

LT Debt to Total Assets (A: Dec. 2023 )=Long-Term Debt & Capital Lease Obligation (A: Dec. 2023 )/Total Assets (A: Dec. 2023 )
=386.604/4247.058
=0.09

Keymed Biosciences's Long-Term Debt to Total Asset Ratio for the quarter that ended in Dec. 2023 is calculated as

LT Debt to Total Assets (Q: Dec. 2023 )=Long-Term Debt & Capital Lease Obligation (Q: Dec. 2023 )/Total Assets (Q: Dec. 2023 )
=386.604/4247.058
=0.09

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Keymed Biosciences  (HKSE:02162) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Keymed Biosciences LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of Keymed Biosciences's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Keymed Biosciences (HKSE:02162) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Keymed Biosciences Inc (HKSE:02162) » Definitions » LT-Debt-to-Total-Asset
Comparable Companies
HKSE:06826 HKSE:01530 HKSE:06990 HKSE:09969 HKSE:01541 HKSE:09966 HKSE:06660 HKSE:01952 HKSE:02105 HKSE:02315 OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA XBRU:ARGX HKSE:02269 BNTX
Traded in Other Exchanges
64Z:Germany
Address
No. 18 BioTown Middle Road, Building D2, Tianfu International BioTown, Chengdu, Sichuan, CHN, 610219
Website
https://www.keymedbio.com
Keymed Biosciences Inc is a biotechnology company with multiple clinical-stage assets. The company is focused on the in-house discovery and development of innovative biological therapies that address large underserved medical needs in the autoimmune and oncology therapeutic areas. The Group is engaged in biopharmaceutical research and development, which is regarded as a single reportable segment. Geographically, it operates in Hong Kong & Mainland China, out of which the majority is from Mainland China.
Executives
Chen Bo 2201 Interest of corporation controlled by you
Eagle Hero Management Limited 2101 Beneficial owner
Trident Trust Company (hk) Limited 2301 Trustee
Moonshot Holdings Limited 2101 Beneficial owner
Hh Kny Holdings Limited
Hillhouse Investment Management, Ltd.
Boyu Capital Group Holdings Ltd
Xyxy Holdings Ltd.
Tong Xiaomeng

Keymed Biosciences (HKSE:02162) Headlines

No Headlines